Home > Insider Trading > Filing (0001209191-22-014469)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
818686	Teva Pharmaceutical Industries Ltd	TEVA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1561458	Hafrun Fridriksdottir	C/O Teva Pharmaceutical Industries Ltd. 124 Dvora Hanevi'A St., Tel Aviv L3 6944020	Executive Vp, Global R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2022-02-28	21,682	$0.00	73,099	No	4	M	Direct
Ordinary Shares	Disposition	2022-02-28	7,590	$8.14	65,509	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Restricted Share Units	Disposition	2022-02-28	21,682	$0.00	21,682	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
43,366			No	4	M	Direct

Footnotes

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resourcesand Compensation Committee, the cash value of one ordinary share.
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vestingof the restricted share units listed in Table II.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255,inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, fullinformation regarding the number of shares sold at each separate price.
Restricted share units were granted on February 28, 2020, with 21,682 having vested on each of February 28, 2021 and February 28, 2022, 21,682 vesting on February 28, 2023 and 21,684 vesting on February 28, 2024.